Global Blood Banking and Blood Products Market Growth (Status and Outlook) 2025-2031

Global Blood Banking and Blood Products Market Growth (Status and Outlook) 2025-2031

The global Blood Banking and Blood Products market size is predicted to grow from US$ 56080 million in 2025 to US$ 85650 million in 2031; it is expected to grow at a CAGR of 7.3% from 2025 to 2031.

Blood banking is the process that takes place in the lab to make sure that donated blood, or blood products, are safe before they are used in blood transfusions and other medical procedures. Blood banking includes typing the blood for transfusion and testing for infectious diseases. A blood product is any therapeutic substance prepared from human blood. This includes: whole blood; blood components; and plasma derivatives. Whole blood is not commonly used in transfusion medicine.

Blood products refer to various human plasma protein products, including albumin, immunoglobulin, coagulation factors, etc. The raw material of blood products is plasma. 92% - 93% of human plasma is water, and only 7% - 8% is protein. Blood products are made by separating and purifying this part of protein.

The primary driver of the blood banking market is the increasing prevalence of chronic diseases and the rising number of surgical procedures globally. Conditions such as cancer, anemia, and trauma often require blood transfusions, boosting the demand for blood and blood products. Additionally, advancements in medical technology, such as improved blood preservation techniques and the development of blood substitutes, have enhanced the efficiency of blood banking systems, further contributing to market growth. One major challenge in the blood banking market is the risk of blood contamination and the transmission of infectious diseases. Despite stringent screening processes, there remains a possibility of contamination, especially in regions with less advanced healthcare systems. Furthermore, the high cost of blood testing and the maintenance of blood banks, coupled with the difficulty in ensuring a consistent blood supply due to low donation rates in some areas, presents significant obstacles to market expansion.

The growing prevalence of immunodeficiency disorders, hemophilia, and other chronic diseases that require plasma-derived therapies is a key driver of the blood product market. Blood products, such as immunoglobulins, clotting factors, and albumin, are essential in treating conditions where patients have compromised immune systems or bleeding disorders. Furthermore, the increasing use of plasma products in emergency care and surgical procedures, along with advancements in fractionation technologies, is boosting market demand. A major challenge in the blood product market is the high cost and complexity of the plasma collection and fractionation process. The production of blood products requires strict regulatory compliance and advanced facilities to ensure the purity and safety of these therapies, driving up costs. Additionally, fluctuations in plasma donation rates and the need for extensive screening to prevent contamination or the spread of infectious diseases can lead to supply shortages, especially in regions with underdeveloped healthcare infrastructure.

LPI (LP Information)' newest research report, the “Blood Banking and Blood Products Industry Forecast” looks at past sales and reviews total world Blood Banking and Blood Products sales in 2024, providing a comprehensive analysis by region and market sector of projected Blood Banking and Blood Products sales for 2025 through 2031. With Blood Banking and Blood Products sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Blood Banking and Blood Products industry.

This Insight Report provides a comprehensive analysis of the global Blood Banking and Blood Products landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Blood Banking and Blood Products portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Blood Banking and Blood Products market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Blood Banking and Blood Products and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Blood Banking and Blood Products.

This report presents a comprehensive overview, market shares, and growth opportunities of Blood Banking and Blood Products market by product type, application, key players and key regions and countries.

Segmentation by Type:
RBCs
Plts
Plasma
Whole Blood
Plasma Fractionation Products

Segmentation by Application:
Hospital
Clinic
Retail Pharmacy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
America’s Blood Centers
Japan Red Cross Society
American Red Cross
Australia Red Cross
Red Cross Society of China
NHS Blood and Transplant
New York Blood Center
Canadian Blood Services
Sanquin Blood Supply Foundation
Blood Bank of Alaska
Vitalant
National Blood Transfusion Council
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics